GRTX - Galera Therapeutics Inc

0.1452
0.145   100.000%

Share volume: 0
Last Updated: 06-03-2024

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
-65.85%
Key data
Stock price
$0.15
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$1.11
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
7.887 M
YIELD 
N/A
SHARES OUTSTANDING 
54.392 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: J. Mel Sorensen
Region: US
Website: galeratx.com
Employees: 30
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Galera Therapeutics, Inc. focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the. treatment of. radiotherapy induced severe oral mucositis in patients with head and neck cancer.

Recent news